info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Gene Editing Market Research Report Information by Technology (CRISPR, TALEN, ZFN, Antisense, and others), Application (Genetic Engineering, Gene Therapy, Cell Line Engineering, and Others), Method (Ex-vivo and In-vivo), End User (Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), and Academic & Government Research Institutes) and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2032


ID: MRFR/HC/0236-CR | 128 Pages | Author: Rahul Gotadki| June 2024

Global Gene Editing Market Overview


The Gene Editing Market size was valued at USD 7.19 billion in 2023 and is projected to grow from USD 8.69 Billion in 2023 to USD 39.79 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 20.94% during the forecast period (2024 - 2032). The growing number of strategic initiatives and increasing funding for genetic research are major factors driving the market growth.


Gene Editing Market2


Gene Editing Market Trends



  • Growing number of Strategic initiatives


Genomic editing refers to the strategies and techniques used to modify the genetic information of any living organism. Genome editing involves the modification of genes in multiple locations using recombinant technology, which increases insertion precision and decreases cell toxicity. It is a collection of technologies that allow scientists to alter an organism's DNA. These technologies enable adding, deleting, or modifying genetic material at specific locations within the genome. Rise in the number of strategic initiatives in the form of mergers, acquisitions, product approval, collaborations, and partnerships among the players to gain a competitive edge and offer advanced treatment options for genomic editing is the major factor drive the growth of market. 


For instance, in April 2022, Thermo Fisher Scientific (US) launched a new GMP-manufactured Gibco CTS TrueCut Cas9 Protein, as high-quality auxiliary materials and documentation are essential, as researchers using genome editing techniques transition from basic research to therapeutic settings. Gibco CTS TrueCut Cas9 Protein is an attractive option for CAR T-cell therapy research employing CRISPR-Cas9 genome editing since it consistently achieves high editing efficiency in all studied cell lines and better than 90% efficiency in human primary T-cells. Similarly, in February 2022, Intellia Therapeutics, Inc. (US) and Regeneron Pharmaceuticals, Inc. (US) announced the positive interim data from an ongoing Phase I clinical study of their lead in vivo genome editing candidate, NTLA-2001 (Investigational Crispr Therapy for Transthyretin (Attr) Amyloidosis). 


Moreover, in February 2022, GenScript Biotech Corporation (US) launched its new CRISPR Genome Editing Cell Line Engineering Service, which enables scientists to create custom cell lines for research and therapeutic applications. The service utilizes GenScript's proprietary CRISPR/Cas9 technology and experienced team of scientists to deliver precise and efficient genome editing. Additionally, it will also expand the company’s position and its commitment to delivering therapeutic applications across the world.


Gene Editing Market Segment Insights


Gene Editing Technology Insights


By Technology the market is classified into CRISPR, TALEN, ZFN, antisense, and others. The CRISPR segment held the majority share in 2022 in the Gene editing Market revenue due to its wide range of applications in vivo to fix the target gene and ex vivo to rewire & redirect cells for genetic diseases and immuno-oncology autoimmune diseases. Furthermore, the increasing number of applications for CRISPR technology an rise in adoption key strategies by major players is expected to drive demand for gene editing over the forecast period. For instance, in 2024, Drug discovery company IRBM (Rome) has signed a non-exclusive agreement granting access to ERS Genomics’ CRISPR/Cas9 patent portfolio. The Italian CRO offers expertise ranging from target validation and hit finding to preclinical candidate nomination across various therapeutic areas, including oncology, infectious diseases and neuroscience. The company has contributed to the discovery and development of four marketed therapeutics for HIV, HCV, ovarian cancer and cutaneous T-cell lymphoma.


Gene Editing Application Insights


By application the market is classified into genetic engineering and clinical application. The genetic engineering segment has dominated the market in 2023, as it allows scientists to directly manipulate the genetic material of an organism to achieve desired traits or characteristics. This technology offers a precise and efficient way to edit genes, which can lead to advancements in agriculture, medicine, and other industries.


Gene Editing Method Insights


Based on Type, the Gene Editing Market is bifurcated into Ex-vivo and In-Vivo products. The in vivo segment has dominated the market in 2023, due to their ability to directly deliver genetic editing tools into living organisms, allowing for targeted and efficient gene editing. This method has gained popularity in recent years as it offers several advantages over traditional methods such as ex vivo delivery. Additionally, In vivo delivery methods are being used in a wide range of applications, including gene therapy, drug development, and agricultural biotechnology. These methods are particularly valuable in the field of gene therapy, where they have shown promising results in treating various genetic disorders such as cystic fibrosis, sickle cell anemia, and muscular dystrophy. Overall, the increasing adoption of in vivo delivery methods is driving the growth of the genetic editing market by providing more effective and efficient ways to edit genes in living organisms.


GENE EDITING MARKET SIZE, BY TYPE, 2019 & 2032 (USD Billion)


GENE EDITING MARKET SIZE, BY TYPE, 2019 & 2032


Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review


Gene Editing End User Insight


By end user, the market is bifurcated into biotechnology and pharmaceutical companies, contract research organizations (CROs), and academic & government research institutes. The biotechnology and pharmaceutical companies’ segment have dominated the market in 2023 and is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to the increase in funding for gene editing for the development of therapeutic products. Some major companies that raised funding for gene editing platform include Beam Therapeutics (US), which raised USD 135 million on March 2019, Graphite Bio (US), which raised USD 195 million in March 2021, and Caribou Biosciences (US), which raised USD 169 million in March 2021.


Furthermore, in September 2022, Integrated DNA Technologies Inc (US) expands customization options for Alt-R Custom CRISPR gRNA Libraries for drug discovery. This expansion allows researchers to quickly assess new therapeutic options.


Gene Editing Regional Insight


By Region, the market is classified into North America, Europe, Asia-Pacific, and Rest of the World.


The North America gene editing market held the largest share in the market. This is attributed to the increase in the prevalence of chronic disease, a growing preference for gene therapies, an increase in private and public sector funding, and rapid advancements in sequencing and gene editing technologies are driving the market for gene editing in the North America region. For instance, in March 2021, Scientists at the University of California (UC), San Francisco, UC Berkeley, and UC Los Angeles received the Food and Drug Administration's approval to jointly launch an early phase, first-in-human clinical trial of a gene correction therapy in sickle cell disease patients using the patient's blood-forming stem cells. Furthermore, according to National Centre for Advancing Translational Sciences reports from June 2022, the National Institutes of Health (NIH) Somatic Cell Gene Editing (SCGE) Programme has given 24 new funds to researchers in the US and Canada. Over the next four years, the SCGE Programme will award a total of USD 89 million in advance gene editing grants.


Asia Pacific is expected to be the fastest-growing region in the gene editing market due to factors such as increasing investments in research and development, advancements in technology, and growing prevalence of genetic disorders in the region. One of the key drivers of growth in the Asia Pacific gene editing market is the increasing focus on personalized medicine and precision medicine in countries like China, Japan, and South Korea. These countries have been making significant investments in genomics research and precision medicine initiatives, which is driving the demand for gene editing technologies.


Additionally, the region has a large population with a high prevalence of genetic disorders, such as thalassemia, sickle cell anemia, and various types of cancer. This has created a significant need for advanced gene editing solutions to develop potential treatments and therapies for these conditions. Furthermore, the Asia Pacific region is home to a thriving biotechnology and pharmaceutical industry, which is further boosting the growth of the gene editing market. Companies in countries like China and India are increasingly focusing on developing innovative gene editing technologies and therapies, which is driving the market growth in the region.


Overall, the Asia Pacific region offers immense growth opportunities for the gene editing market, and with the advancements in technology and increasing investments in research and development, the market is expected to witness rapid growth in the coming years.


Gene Editing Key Market Players & Competitive Insights


The key market players in the gene editing industry include companies like Bio-Rad Laboratories, Inc, Lonza GenScript, Sangamo Therapeutics, and Thermo Fisher Scientific. These companies are at the forefront of developing cutting-edge gene-editing technologies and are continuously investing in research and development to expand their product offerings and market reach.


The gene editing market is highly competitive, with a growing number of players entering the space and large investments being made in developing new and innovative gene-editing technologies. Additionally, partnerships and collaborations between industry players and academic institutions are becoming increasingly common, driving further innovation in the field. For instance, in November 2021, GenScript launched the GenWand Double-Stranded DNA (dsDNA) service for the manufacture of CRISPR knock-in homology-directed repair (HDR) templates in T-cell engineering.


companies in the gene editing industry are also focused on obtaining regulatory approvals for their products and expanding their presence in key markets worldwide. The competition is intense, with players vying for market share and striving to differentiate themselves through technological advancements, strategic partnerships, and strong intellectual property portfolios.


Overall, the gene editing market is dynamic and rapidly evolving, with key players working tirelessly to stay ahead of the curve and shape the future of gene editing technologies.


Key Companies in the Gene Editing Market include.



  • GE Healthcare (US)

  • Thermo Fisher Scientific Inc (US)

  • Bio-Rad Laboratories, Inc (US)

  • Lonza (Switzerland)

  • GenScript (US)

  • Horizon Discovery Ltd (UK)

  • OriGene Technologies, Inc (US)

  • Integrated DNA Technologies, Inc (US)

  • New England Biolabs, Inc (US)

  • Sangamo Therapeutics (US)


Gene Editing Industry Developments


September 2022: Integrated DNA Technologies Inc (US) expands customization options for Alt-R Custom CRISPR gRNA Libraries for drug discovery. This expansion allows researchers to quickly assess new therapeutic options.


July 2020: Horizon Discovery Group plc (UK) announced an agreement with TrueBinding, Inc a biopharmaceutical company, has signed an agreement of commercial licenses for Horizon’s cGMP compliant CHOSOURCE platform. TrueBinding used the platform for the development and commercialization of many biotherapeutic products for utilize in immuno-oncology and other diseases.


November 2021: GenScript (US) has launched the Gen Wand Double-Stranded DNA (dsDNA) service for the manufacture of CRISPR knock-in homology-directed repair (HDR) templates in T-cell engineering.


April 2019: GenScript (US) launched a Single-stranded DNA Service for CRISPR-based gene editing. The newly launched service provides researchers with high-quality, pure ssDNA for CRISPR-based gene insertion, with the goal of accelerating the development of gene therapy, cell therapy, and transgenic animal models for cancer research and treatment.


Gene Editing Market Segmentation


Gene Editing Technology Outlook



  • CRISPER

  • TALEN

  • ZFEN

  • Antisense

  • Other


Gene Editing Application Outlook



  • Genetic Engineering

    • Cell line engineering

    • Animal genetic engineering

    • Plant genetic engineering

    • Others



  • Clinical applications

    • Diagnostics

    • Therapy Development



  • Others


Gene Editing Method Outlook



  • Ex-vivo

  • In-vivo


Gene Editing End-Users Outlook



  • Biotechnology and Pharmaceutical Companies

  • Contract Research Organizations (CROs)

  • Academic and Government Research Institutes


Gene Editing Regional Outlook


North America



  • US

  • Canada


Europe



  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Rest of Europe


Asia-Pacific



  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Rest of Asia-Pacific


Rest of the World



  • Middle East

  • Africa

Report Attribute/Metric Details
Market Size 2023 USD 7.19 billion
Market Size 2024 USD 8.69 billion
Market Size 2032 USD 39.79 billion
Compound Annual Growth Rate (CAGR) 20.94% (2024-2032)
Base Year 2023
Forecast Period 2024-2032
Historical Data 2019 to 2022
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends.
Segments Covered Technology, Application, Method, Application, Region
Key Companies Profiled GE Healthcare (US), Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories, Inc (US), Lonza (Switzerland), GenScript (US), Horizon Discovery Ltd (UK), OriGene Technologies, Inc (US), Integrated DNA Technologies, Inc (US), New England Biolabs, Inc (US), Sangamo Therapeutics (US
Key Market Opportunities Increasing application of areas of gene editing.
Key Market Dynamics Increasing funding for genetic research, Rising incidence of genetic disorders.


Frequently Asked Questions (FAQ) :

The global gene editing is market is anticipated to reach USD 39.79 billion at a CAGR of 20.94% during the forecast period of 2024 to 2032.

The US gene editing market is anticipated to reach USD 39.79 billion at a CAGR of 20.94% during the forecast period of 2024 to 2032.

The Gene editing Market is expected to register a CAGR of 20.94% during the forecast period of 2024 to 2032.

The North America gene editing market accounted for USD 11.32 billion in 2022 and is expected to exhibit a 21.19% CAGR during the study period.

GE Healthcare (US), Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories, Inc (US), Lonza (Switzerland), GenScript (US), Horizon Discovery Ltd (UK), OriGene Technologies, Inc (US), Integrated DNA Technologies, Inc (US), New England Biolabs, Inc (US), Sangamo Therapeutics (US).

The CRISPR segment held the majority share in 2022 contributing to around 35.5% with respect to the Gene editing Market.

The gene engineering segment held the majority share in 2022 contributing to around 44.2% with respect to the Gene editing Market.

The biotechnology and pharmaceutical companies segment dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2024-2032.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.